Patents

A strong patent protection is a prerequisite for investments in the development of products for commercialization.

Active Biotech’s patent portfolio includes biochemical structures, pharmaceutical preparations, methods, uses, and processes related to the company’s operations in key markets.

Patents and patent applications primarily cover commercially important markets such as Europe, the USA, and Japan, but the most important patent families also include patents and applications in several other countries (RoW). Inventions related to tasquinimod, laquinimod, and naptumomab are specifically protected by several patent families. The patent portfolio also includes protection for inventions related to substances structurally similar to tasquinimod and laquinimod.

Active Biotech continuously works to optimize the patent portfolio to ensure the best possible protection for its projects in the most important markets. The portfolio of strategically important patents and applications protects the use of tasquinimod in the treatment of various hematological cancers such as myelofibrosis, multiple myeloma, and myelodysplastic syndrome, as well as the use of laquinimod for the treatment of eye diseases associated with inflammation or excessive vascularization.